Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zhangyanming tablets added to fluorometholone and epidermal growth factor eye drops for moderate to severe dry eye disease
ChiCTR2300070960Phase 4Completed
- Sponsor
- Shenzhen Eye Hospital
- Start
- Apr 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of zhangyanming, fluorometholone and epidermal growth factor in dry eye syndrome (DED) (2 arms), sponsored by Shenzhen Eye Hospital. Primary endpoint: Comprehensive effect of dry eye. Started Apr 2023; status: completed.
02
Drugs
zhangyanmingfluorometholoneepidermal growth factor
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on ChiCTR2300070960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070960.